Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067365 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
A Phase 3 study of Secondary Hypogonadism, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
- 18
- Study locations
NCT01067365: Completed Phase 3 study of Secondary Hypogonadism, sponsored by Repros Therapeutics.
NCT01067365 is a Phase 3 study of Secondary Hypogonadism that has completed, run by Repros Therapeutics. The registered enrollment target is 104 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01067365, a Phase 3 study of Secondary Hypogonadism, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
- 18
- Study locations
Study Summary
Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
Conditions Studied
Interventions
- DRUG Androxal
Study Locations (18)
California
- Northern California Research Corp - Carmichael
- Prime-Care Clinical Research - Mission Viejo
- Harbor-UCLA Medical Center - Torrance
Alabama
- Alabama Clinical Therapeutics, LLC - Birmingham
- Medial Affiliated Research Center, Inc. - Huntsville
Nevada
- Office of Michael Mall, MD - Las Vegas
- Office of Stephen Miller, MD - Las Vegas
New Jersey
- Advanced Biomedical Research, Inc. - Hackensack
- Office of Gary S. Karlin, MD - Lawrenceville
Connecticut
- Chase Medical Research, LLC - Waterbury
Florida
- Southeastern Research Group, Inc. - Tallahassee
Indiana
- Northeast Indiana Research, LLC - Fort Wayne
Kentucky
- Commonweatlh Biomedical Research - Madisonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
What the finished NCT01067365 record still lists
NCT01067365 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Secondary Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Androxal is the first listed.
NCT01067365 lists 18 locations in 13 states (California, Alabama, Nevada).
Frequently Asked Questions
What is clinical trial NCT01067365 about?
NCT01067365 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism". Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
What is the current status of trial NCT01067365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2006-03. Estimated completion is 2007-05.
What conditions does trial NCT01067365 study?
This clinical trial studies the following conditions: Secondary Hypogonadism.
What interventions are being tested in trial NCT01067365?
The interventions under investigation include: Androxal (DRUG).
Who is sponsoring clinical trial NCT01067365?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01067365 being conducted?
This trial has 18 study locations across Alabama, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01067365's enrollment target sits among peer trials
104 1671st of 2000 higher than 327 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia